Free shipping on all orders over $ 500

Torin 2

Cat. No. M2022
Torin 2 Structure
Size Price Availability Quantity
5mg USD 60  USD60 In stock
10mg USD 108  USD108 In stock
50mg USD 320  USD320 In stock
100mg USD 480  USD480 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Torin 2 is a potent and selective inhibitor of cellular mTOR activity (EC50 = 0.3 nM). Torin 2 inhibits mTORC1, thus activates TFEB by promoting its nuclear translocation with EC50 of 1.666 mM. Torin 2 displays more than 800-fold selectivity for mTOR over PI3K (cellular EC50 values are 0.25 and 200 nM for mTOR and PI3K respectively) and greater than 100-fold binding selectivity relative to 440 other protein kinases. Torin 2 has significantly improved bioavailability (54%), metabolic stability, and plasma exposure compared to Torin 1. Torin 2 exhibits >95% pharmacodynamic response and half-time of 11.7 min in the mouse liver microsome stability study in vivo.

Protocol (for reference only)
Cell Experiment
Cell lines MZ-CRC-1 and TT cells
Preparation method Cell viability and motility assays
For viability, MZ-CRC-1 and TT cells were seeded in quadruplicate in 96-well plates (10,000 cells per well) in culture media with 2.5% and 4% FBS, respectively. After 24 hours, cells were treated with the indicated compounds. At the indicated time point, cells were incubated for 3 hours with 10 μL of CellTiter96 AQueous One solution in 100 μL of culture media (Promega) and absorbance was measured at 490 nm. For migration assays, Transwell inserts with membranes of 8 μmol/L pore size (Corning-Costar) were used. Membranes were coated with 10 μg/mL collagen and kept at 4°C overnight. Cells were serum starved for 8 hours, detached by trypsin, and counted by hemocytometer. A total of 1 × 105 cells were plated in the upper chambers in serum-free medium, containing the vehicle or the indicated compounds (rapamycin: 100 nmol/L; everolimus/Rad001: 100 nmol/L, and Torin 2: 100 nmol/L). The lower chambers were filled with MZ-CRC-1 and TT culture media containing 2.5% and 4% FBS, respectively, supplemented with 20 ng/mL EGF (Sigma). After 24 hours, cells were fixed in methanol and stained with hematoxylin. Cells on the top surface of the membranes were wiped off with cotton swabs. Membranes were removed from the inserts, placed on microscope slides, and images acquired by Scanscope. Migrated cells were counted and the number of migrated cells per mm2 was calculated.
Concentrations 10, 50nM
Incubation time 5 days
Animal Experiment
Animal models Six-week old male C57BL/6 mice model
Formulation 100% N-methyl-2-pyrrolidone and then diluted 1:4 with sterile 50% PEG400 prior to injection
Dosages 20 mg/kg for 6h
Administration oral gavage
Chemical Information
Molecular Weight 432.4
Formula C24H15F3N4O
CAS Number 1223001-51-1
Solubility (25°C) DMSO 20 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.


[1] Berry T, et al. Cancer Cell. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.

[2] Liu Q, et al. J Med Chem. Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer.

Related mTOR Products

Zederone, a germacrane-type sesquiterpene, has potently cytotoxic against human white blood cancer cells and human prostate cancer cells. Zederone significantly inhibits the proliferation and downregulates the protein expressions of mTOR, and phosphorylated p70 S6 kinase (p-p70s6K) in SKOV3 cells.


MHY-1685, a novel mammalian target of rapamycin (mTOR) inhibitor, provides opportunities to improve hCSC-based myocardial regeneration.


RMC-6272 (RM-006) is a bi-steric mTORC1-selective inhibitor. RMC-6272 exhibits potent and selective (> 10-fold) inhibition of mTORC1 over mTORC2. RMC-6272 shows improved inhibition of mTORC1 in comparison to Rapamycin, and induces more cell death in TSC2 null tumors.


eCF309 is a potent and highly selective mTOR inhibitor with remarkably low off-target activities (IC50 = 10-15 nM, both in vitro and in cells).


PQR626, a rapamycin derivative, is a potent, selective, orally active, and brain-penetrant mTOR inhibitor, with an IC50 and Ki of 5 nM and 3.6 nM, respectively. PQR626 can be can be used for the research of neurological disorders.

Abmole Inhibitor Catalog

Keywords: Torin 2 supplier, mTOR, inhibitors, activators

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.